Does Medicaid Cover Mounjaro? T2D Coverage Across State Programs

Trust signals

> Reviewed by FormBlends Medical Team · Last updated May 2026 · 11 sources cited · Author: FormBlends Editorial

Key Takeaways

• State Medicaid programs cover Mounjaro for T2D in essentially all states because diabetes care is mandatory coverage
• This contrasts sharply with Zepbound, which only about 14 state Medicaid programs cover
• PA criteria vary by state but generally require T2D diagnosis, A1C documentation, and metformin trial
• Medicaid copays are statutorily limited to $0-$4 per fill, making it the most affordable path when eligible
• Mounjaro savings cards cannot be used with Medicaid; Medicaid copays are already minimal

Direct answer

Yes, state Medicaid programs cover Mounjaro for type 2 diabetes treatment. Diabetes care is a federally mandated Medicaid benefit category, which means coverage is consistent across all 50 states (with state-specific PA criteria and step-therapy details). As of May 2026, confirm with your state Medicaid Preferred Drug List or managed-care plan. This contrasts with Zepbound coverage, which depends on whether your state has chosen to add weight-loss medications to its optional benefit set (about 14 states have). Mounjaro PA typically requires documented T2D diagnosis (ICD-10 E11), recent A1C ≥ 7.0%, metformin trial, and (on many states' PDLs) trial of one additional oral T2D agent. Copays are $0-$4 per fill where coverage applies.

Table of contents

1. How Medicaid drug coverage works for T2D vs weight loss
2. Mounjaro coverage uniformity across states
3. Standard PA criteria
4. Step therapy variation by state
5. Medicaid copay structure
6. Coverage exception and fair hearing
7. Dual-eligible considerations
8. State PDL placement examples
9. Managed-care plan administration
10. FAQ
11. Sources

How Medicaid drug coverage works for T2D vs weight loss

The federal Medicaid statute (§1927 of the Social Security Act) divides prescription drug coverage into mandatory and optional categories. Drugs treating diagnosed medical conditions like type 2 diabetes are in the mandatory category. States must cover them, subject to PA and step-therapy rules they set.

Weight-loss medications are explicitly in the optional category. States can choose to cover them or not. About 14 states and DC currently cover Zepbound; the rest do not.

This split means:

• Mounjaro for T2D: Covered everywhere
• Zepbound for weight loss: Covered in about 14 states
• Zepbound for OSA (after December 2024 FDA approval): Coverage expanding as state PDLs update

Mounjaro coverage uniformity across states

State Medicaid programs cover Mounjaro on their PDLs across all 50 states. Specific tier placement and PA rules vary. The typical pattern:

• Tier 3 specialty placement on most state PDLs
• Prior authorization required
• Step therapy through metformin and one or more additional agents
• Quantity limits per fill (typically 30-day supply)
• Reauthorization at 6 months with documented clinical benefit

Standard PA criteria

PA elements common across state Medicaid programs:

• Documented type 2 diabetes diagnosis (ICD-10 E11.0 - E11.9)
• Recent A1C measurement (within 90 days), generally ≥ 7.0%
• Age ≥ 18 (separate criteria for adolescents in some states)
• Trial of metformin at maximum tolerated dose for ≥ 3 months (unless contraindicated)
• Most states: trial of one additional oral T2D agent before Mounjaro
• Some states: trial of one GLP-1 before Mounjaro
• Prescriber attestation of continued diabetes self-management counseling
• Reauthorization: A1C improvement or maintenance documented

Step therapy variation by state

State Medicaid	Mounjaro step therapy
California Medi-Cal	Metformin + one additional oral agent
Texas Medicaid	Metformin + one or two oral agents
Florida Medicaid	Metformin + DPP-4 or SGLT2 + GLP-1 trial
New York Medicaid	Metformin + one additional oral agent
Pennsylvania Medicaid	Metformin + GLP-1 trial
Illinois Medicaid	Metformin + one additional oral agent

Step-therapy exceptions are available through each state's process. Documentation requirements for exceptions vary but generally include prior treatment failure, intolerance, contraindication, or expected adverse interaction.

Medicaid copay structure

Federal Medicaid law limits beneficiary cost-sharing. Standard adult copays for Tier 3 prescription drugs:

State Medicaid	Adult copay (Tier 3)
California Medi-Cal	$1
Texas Medicaid	$3
Florida Medicaid	$0-$3 (varies by income)
New York Medicaid	$3
Pennsylvania Medicaid	$3
Massachusetts MassHealth	$3.65
Children under CHIP	$0-$2

These are beneficiary out-of-pocket costs at the pharmacy. State Medicaid programs pay significantly more per fill but receive deep rebates under the Medicaid Drug Rebate Program (the deepest of any payer).

Coverage exception and fair hearing

If a state Medicaid denies a Mounjaro PA:

1. Coverage exception request: Submit through the state's exception process. Include A1C history, prior treatment documentation, and prescriber attestation. Decision within a state-defined timeframe (usually 7 days for standard, 72 hours for urgent).
2. Fair hearing request: If a benefit is denied, beneficiaries can request a fair hearing through the state Medicaid agency. The hearing is conducted by an administrative law judge or hearing officer. Decisions are binding.
3. Federal court review: Available if the state denies the fair hearing.

For T2D patients, exception approval rates are generally good when documentation is complete. Mounjaro denials usually reflect documentation gaps rather than substantive coverage objections.

Dual-eligible considerations

Medicare-Medicaid dual-eligibles (about 12.5 million Americans) have a specific prescription coverage hierarchy:

• Medicare Part D is the primary prescription benefit
• Mounjaro for T2D is covered by Part D
• Extra Help (Low Income Subsidy) reduces Part D copays to $0-$11.40 for qualifying duals
• State Medicaid generally does not provide wrap-around coverage for prescription drugs that Part D covers
• The 2026 $2,000 Part D OOP cap caps annual prescription spending

State PDL placement examples

Mounjaro typically appears on state PDLs as Tier 3 specialty:

• California Medi-Cal: Preferred with PA
• Texas Medicaid: Preferred with PA
• Florida Medicaid: Preferred with PA
• New York Medicaid: Preferred with PA
• Most other states: Preferred or non-preferred with PA

Non-preferred status requires additional exception documentation but generally still results in coverage for qualifying T2D patients.

Managed-care plan administration

Most states deliver Medicaid through managed-care organizations (MCOs). The state sets the PDL; MCOs administer benefits. Common MCOs include Centene, Molina, Anthem (Wellpoint), UnitedHealthcare Community Plan, and various regional plans.

MCOs follow the state PDL for Mounjaro coverage. PA processes are MCO-specific:

• MCO-specific PA forms and submission portals
• MCO-specific clinical reviewers
• MCO-specific timeframes within state-mandated maximums

Contrary view: state Medicaid Mounjaro coverage isn't unlimited

The general pattern of universal state Medicaid Mounjaro coverage has exceptions. Some state PDLs apply tighter step therapy than commercial plans:

• Required trial of two or more oral T2D agents before Mounjaro on some PDLs
• Required prior GLP-1 trial (Ozempic or Trulicity) on others
• Stricter A1C threshold requirements (some states require A1C ≥ 8.0% for tirzepatide approval)
• Annual cap on Mounjaro prescriptions per beneficiary in rare cases

The clinical justification: state Medicaid programs face budget constraints that make aggressive step therapy attractive. Metformin and older GLP-1s are significantly cheaper net of rebates than tirzepatide. For patients with adequate response to less-expensive agents, the system isn't optimizing wrong; it's optimizing for cost efficiency under fixed budgets.

The legitimate complaint is when step therapy creates delays for patients with rapid disease progression. The exception process addresses these cases when documented.

Decision framework

If you have Medicaid and T2D: Mounjaro is covered. Submit PA with A1C history, metformin documentation, and T2D ICD-10 codes.

If denied for step therapy: File exception with prior treatment documentation.

If denied for A1C threshold: Get current A1C drawn and resubmit.

If you're dual-eligible: Medicare Part D rules apply. Extra Help reduces copays.

If you don't have T2D: Mounjaro is not the path. Look at Zepbound under your state's AOM rules.

What to verify before using this answer

The useful next step for Does Medicaid Cover Mounjaro? T2D Coverage Across State Programs is to verify the details that can change the decision: current labeling, insurance rules, pharmacy instructions, dose timing, contraindications, and whether the evidence applies to your diagnosis rather than only to weight loss headlines.

For this coverage and access page, the most relevant search terms are does, medicaid, cover, mounjaro. Those terms point to a practical decision, so the answer should be checked against a current prescription label, payer policy, trial result, or clinician recommendation before you act.

FormBlends keeps this page focused on patient-level decision points: what is known, what is uncertain, what should be handled by a licensed clinician, and what should be avoided because it creates dosing, safety, or access risk.

FAQ

Does Medicaid cover Mounjaro? Yes for T2D in all states. PA and step therapy vary by state.

What does Mounjaro cost on Medicaid? $0-$4 per fill where covered. Among the lowest costs across any coverage type.

What does PA require? T2D diagnosis, A1C, and metformin trial documentation typically.

What's the step therapy? Metformin universally; many states add one or more additional oral agents and/or prior GLP-1.

Can I use the Mounjaro savings card? No. Manufacturer copay cards cannot be used with Medicaid.

What if I'm dual-eligible? Medicare Part D is primary. Mounjaro covered under Part D for T2D.

Does Medicaid cover Mounjaro for weight loss? No. Label is T2D. PA requires T2D diagnosis.

How do I appeal a denial? Coverage exception request through your state's process; fair hearing if denied.

Sources

1. FDA. Mounjaro (tirzepatide) prescribing information. Updated 2024.
2. Frias JP et al. Tirzepatide versus Semaglutide in T2D (SURPASS-2). NEJM. 2021.
3. Rosenstock J et al. Tirzepatide monotherapy in T2D (SURPASS-1). The Lancet. 2021.
4. Social Security Act §1927. Medicaid prescription drug coverage requirements.
5. CMS. Medicaid Drug Rebate Program guidance. Updated 2025.
6. American Diabetes Association. Standards of Care in Diabetes 2026.
7. California Medi-Cal Pharmacy Benefits. T2D therapy PA criteria. 2026.
8. Texas Medicaid Pharmacy Program. Preferred Drug List. 2026.
9. Florida Medicaid Pharmacy Services. PDL. 2026.
10. Kaiser Family Foundation. State Medicaid prescription drug coverage. 2026 tracker.
11. Eli Lilly. Mounjaro Savings Card terms. Accessed May 2026.

Footer disclaimers

Platform Disclaimer. FormBlends provides educational information about Medicaid prescription coverage. We do not enroll patients in Medicaid, file Medicaid claims, or provide benefits counseling. State Medicaid rules vary; consult your state Medicaid agency or your managed-care plan for binding coverage determinations.

Compounded Medication Notice. Compounded tirzepatide is prepared by state-licensed 503A pharmacies under valid individual prescriptions. It is not FDA-approved and is not therapeutically equivalent to Mounjaro. State Medicaid programs do not include compounded medications on Preferred Drug Lists.

Results Disclaimer. State Medicaid coverage details, PA criteria, step-therapy sequences, and copay amounts reflect publicly available state PDL documentation as of writing. State policies update with budget cycles. Verify current rules with your state Medicaid agency before relying on the examples shown.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Medi-Cal, MassHealth, and other named state programs are operated by their respective state governments. Ozempic is a registered trademark of Novo Nordisk; Trulicity is a registered trademark of Eli Lilly. FormBlends has no affiliation with any state Medicaid program or with CMS.